SEER-Medicare Analysis of Treatment Patterns in Elderly Patients With Mantle Cell Lymphoma

By: Gavin Calabretta, BS
Posted: Friday, October 14, 2022

Aiming to better characterize how elderly patients with mantle cell lymphoma are treated, Viktor Chirikov, MS, PhD, of OPEN Health Evidence and Access, Bethesda, Maryland, and colleagues recently performed an analysis of a Surveillance, Epidemiology, and End Results (SEER)-Medicare–linked database in which they examined real-world therapeutic utilization, costs, and survival outcomes at different stages of therapy. The retrospective study’s findings were presented at the 2022 American Society of Clinical Oncology (ASCO) Quality Care Symposium (Abstract 19).

The investigators enrolled 559 patients with newly diagnosed mantle cell lymphoma. Patients had a median age of 75 years and a mean Charlson Comorbidity index of 1.44. Stage IV disease was present in 45.3% of patients, and 12.2% of patients had a poor performance status. Respectively, 18%, 54.6%, and 27.4% of patients received first-, second-, and third-line treatment regimens.

The study authors reported that the most common regimens were bendamustine plus rituximab (51.7%) in the first-line setting and ibrutinib in the second- (17%) and third-line (15.7%) settings. Corresponding to the first, second, and third lines of treatment, 6.3%, 14.8%, and 8.5% of patients received radiation therapy, and 0.4%, 5.1%, and 8.6% received stem cell transplantation. Additionally, there was a median duration of 245 days between the start of the first and second lines of treatment, 127 days between the second and third lines of treatment, and 222 days between the third and fourth lines of treatment. Moreover, the median overall survival from diagnosis until the end of follow-up was 47.2 months (95% confidence interval [CI] = 40.9–53.7 months), and the 12-month survival rate was 81.1% (95% CI = 77.5%–84.9%), 71.4% (95% CI = 65.5%–77.9%), and 69.9% (95% CI = 61.8%–79.1%) for the first, second, and third respective lines of treatment.

“New treatments are needed to improve clinical outcomes and reduce health-care resource utilization and overall health-care costs in mantle cell lymphoma,” the authors concluded.

Disclosure: For full disclosures of the study authors, visit asco.org.

2022 ASCO Quality Care Symposium

---